New vaccine aims to fight Hard-to-Treat EBV cancers
NCT ID NCT07525024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dendritic cell vaccine (KSD-101)
- What this could lead to
- If it works, this could offer a new treatment option for people with EBV-related blood cancers who have limited choices.
- What could go wrong
- This is an early, small study (80 people) without a comparison group, so results may not apply broadly. The vaccine may not shrink tumors or prevent relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin-Hainan Hospital，Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
Qionghai, Hainan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Could bone marrow from deceased donors cure blood cancers?